Nadine Rouphael

Jan 16, 2025 | nature.com | Bo Zhang |Shiyu Chen |Nadine Rouphael |Angela R. Branche |David J. Diemert |Daniel S. Graciaa | +15 more

AbstractNeutralizing antibody titer has been a surrogate endpoint for guiding COVID-19 vaccine approval and use, although the pandemic’s evolution and the introduction of variant-adapted vaccine boosters raise questions as to this surrogate’s contemporary performance.

Jan 10, 2025 | nature.com | Cole Maguire |Nadine Rouphael |William Messer |Matthew Altman |Patrice Becker |Steven E. Bosinger | +9 more

AbstractCoronavirus disease 2019 (COVID-19) poses significant risks for solid organ transplant recipients, who have atypical but poorly characterized immune responses to infection. We aim to understand the host immunologic and microbial features of COVID-19 in transplant recipients by leveraging a prospective multicenter cohort of 86 transplant recipients age- and sex-matched with 172 non-transplant controls.

Jan 3, 2024 | nature.com | Nadine Rouphael

Sep 13, 2023 | thelancet.com | Gustavo Dayan |Nadine Rouphael |Stephen Walsh |Nicole A. Grunenberg

Research in context Evidence before this study We searched PubMed from database inception to Dec 20, 2022, with no language restrictions, for studies reporting the efficacy or effectiveness of vaccines against emergent SARS-CoV-2 variants, including omicron (B.1.1.529), using the search terms “vaccine”, “efficacy OR effectiveness”, “SARS-CoV-2”, “omicron OR variant of concern OR emerging variant”, and “clinical trial”, and for studies reporting data from updated or bivalent vaccine candidates...